PharmaDiagnostics, with the slogan "Accelerating drug discovery with innovative analytical assays for the pharmaceutical and biotech industries," specializes in developing analytical methods to expedite the drug discovery process. The company offers a variety of assay services, including human albumin binding, human orosomucoid, membrane, and redox potential assays. Their assay systems encompass experimental pKa, experimental log D, P-glycoprotein interaction, Cytochromes P450 interactions, and the solubility of new chemical entities in both fasted and fed intestinal conditions. Founded in 2007, PharmaDiagnostics NV is located in Zellik, Belgium.
With a focus on the biotechnology and healthcare industries, PharmaDiagnostics NV received a $3.70M Series B investment on 21 January 2010 from Capital-E. The company's innovative approach to drug discovery and strong investor backing position it as a noteworthy player in the analytical assay space, catering to the specific needs of the pharmaceutical and biotech industries.
